CD8A and neoplasm: These findings are analogous to TCR–major histocompatibility complex class I dependent upregulation of NKG2D in conventional CD8+ T cells, allowing them to target tumor cells with loss of major histocompatibility complex molecules in an NKG2D-dependent manner.43